Frontiers in Oncology (May 2025)
Diagnostic performance of the triglyceride-glucose index in predicting occurrence of cancer: a meta-analysis
Abstract
ObjectiveThis meta-analysis aimed to evaluate the diagnostic performance of the triglyceride-glucose (TyG) index in predicting cancer occurrence.MethodA comprehensive literature search was conducted in Embase, Medline, Cochrane Library, and Google Scholar from inception to July 2024. Observational studies reporting the diagnostic efficacy of the TyG index in predicting cancer occurrence using ROC curve analysis were included. Pooled sensitivity, specificity, and area under the summary receiver operating characteristic (SROC) curve were calculated using a bivariate random-effects model.ResultsEleven studies with 46,658 participants were included. Patients with cancer had a significantly higher TyG index than those without cancer (mean difference: 0.34, 95% CI: 0.23-0.45). The pooled sensitivity and specificity of the TyG index for predicting cancer occurrence were 0.68 (95% CI: 0.62-0.74) and 0.65 (95% CI: 0.54-0.74), respectively. The area under the SROC curve was 0.72 (95% CI: 0.68-0.75), indicating good discriminatory ability. Subgroup analysis of female participants yielded similar results, with an AUC of 0.73 (95% CI: 0.69-0.77).ConclusionThe TyG index demonstrates good discriminatory ability and may have potential as an adjunct screening tool to help identify individuals at a higher risk of developing cancer. However, this should be interpreted alongside other established risk factors, as many confounding factors (including cancer type, genetic predisposition, and other malignancy risk factors) must be considered. Further research is needed to establish optimal cut-off values, which likely vary across different cancer types, and to investigate their diagnostic accuracy in diverse populations.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42024573712.
Keywords
